---
pmid: '22286129'
title: BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
authors:
- Hantschel O
- Warsch W
- Eckelhart E
- Kaupe I
- Grebien F
- Wagner KU
- Superti-Furga G
- Sexl V
journal: Nat Chem Biol
year: '2012'
full_text_available: false
doi: 10.1038/nchembio.775
---

# BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
**Authors:** Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU, Superti-Furga G, Sexl V
**Journal:** Nat Chem Biol (2012)
**DOI:** [10.1038/nchembio.775](https://doi.org/10.1038/nchembio.775)

## Abstract

1. Nat Chem Biol. 2012 Jan 29;8(3):285-93. doi: 10.1038/nchembio.775.

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.

Hantschel O(1), Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU, 
Superti-Furga G, Sexl V.

Author information:
(1)CeMM-Research Center for Molecular Medicine of the Austrian Academy of 
Sciences, Vienna, Austria.

Comment in
    Nat Chem Biol. 2012 Feb 15;8(3):228-9. doi: 10.1038/nchembio.900.

Constitutive activation of STAT5 is critical for the maintenance of chronic 
myeloid leukemia (CML) characterized by the BCR-ABL oncoprotein. Tyrosine kinase 
inhibitors (TKIs) for the STAT5-activating kinase JAK2 have been discussed as a 
treatment option for CML patients. Using murine leukemia models combined with 
inducible ablation of JAK2, we show JAK2 dependence for initial lymphoid 
transformation, which is lost once leukemia is established. In contrast, initial 
myeloid transformation and leukemia maintenance were independent of JAK2. 
Nevertheless, several JAK2 TKIs induced apoptosis in BCR-ABL(+) cells 
irrespective of the presence of JAK2. This is caused by the previously unknown 
direct 'off-target' inhibition of BCR-ABL. Cellular and enzymatic analyses 
suggest that BCR-ABL phosphorylates STAT5 directly. Our findings suggest 
uncoupling of the canonical JAK2-STAT5 module upon BCR-ABL expression, thereby 
making JAK2 targeting dispensable. Thus, attempts to pharmacologically target 
STAT5 in BCR-ABL(+) diseases need to focus on STAT5 itself.

DOI: 10.1038/nchembio.775
PMID: 22286129 [Indexed for MEDLINE]
